Researchers Shine Light on Molecular Landscape and Clinical Features of Rare Kidney Cancer

Renal cell carcinoma with translocation (tRCC) is a rare and aggressive form of kidney cancer. It accounts for about 5 percent of all renal cell carcinomas in adults and about 50 percent in children. Relatively little is known about this cancer subtype, including its molecular basis and the best clinical treatment.

In a new comprehensive multicenter study of 152 samples, researchers at the Dana-Farber Brigham Cancer Center helped shed light on the molecular landscape and clinical features of the disease, finding that genetic alterations are rare in tRCC, with the exception of the fusion of genes from which it takes its name. . Their work further suggests that tRCCs may be sensitive to treatment with immune checkpoint inhibitors.

We believe that our findings concerning the potential of combinations of immunotherapies could be immediately exploitable in the clinic. Because this cancer is so rare, it is difficult to dedicate clinical trials to it. A thorough study of its molecular and clinical characteristics can help us develop a better roadmap for treatment. “

Ziad El Bakouny, MD, MSc, senior author, internal medicine resident, Brigham and Women’s Hospital


Journal reference:

Bakouny, Z., et al. (2022) Integrative clinical and molecular characterization of translocation renal carcinoma. Cell reports.

Comments are closed.